319 related articles for article (PubMed ID: 25865153)
1. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.
Menting SP; van den Reek JM; Baerveldt EM; de Jong EM; Prens EP; Lecluse LL; Wolbink GJ; Van der Kleij D; Spuls PI; Rispens T
Br J Dermatol; 2015 Sep; 173(3):855-7. PubMed ID: 25865153
[No Abstract] [Full Text] [Related]
2. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
[No Abstract] [Full Text] [Related]
4. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
[No Abstract] [Full Text] [Related]
5. Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks.
Toro-Montecinos M; Ballescá F; Ferrandiz C; Teniente-Serra A; Martinez-Caceres E; Carrascosa JM
J Dermatolog Treat; 2019 Feb; 30(1):35-39. PubMed ID: 29683393
[TBL] [Abstract][Full Text] [Related]
6. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
7. No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
Rodríguez-Jiménez P; Chicharro P; Godoy A; Llamas-Velasco M; García M; Daudén E
Br J Dermatol; 2017 Sep; 177(3):862-863. PubMed ID: 28508387
[No Abstract] [Full Text] [Related]
8. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
9. Interaction between Smoking and HLA-C*06:02 on the Response to Ustekinumab in Psoriasis.
Svedbom A; Nikamo P; Ståhle M
J Invest Dermatol; 2020 Aug; 140(8):1653-1656.e1. PubMed ID: 32014510
[No Abstract] [Full Text] [Related]
10. Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Pan S; Tsakok T; Dand N; Lonsdale DO; Loeff FC; Bloem K; de Vries A; Baudry D; Duckworth M; Mahil S; Pushpa-Rajah A; Russell A; Alsharqi A; Becher G; Murphy R; Wahie S; Wright A; Griffiths CEM; Reynolds NJ; Barker J; Warren RB; David Burden A; Rispens T; Standing JF; Smith CH;
Clin Transl Sci; 2020 Mar; 13(2):400-409. PubMed ID: 31995663
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
[No Abstract] [Full Text] [Related]
12. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
13. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
[No Abstract] [Full Text] [Related]
14. Neutrophil-to-lymphocyte ratio decreases after treatment of psoriasis with therapeutic antibodies.
Zhang L; Wiles C; Martinez LR; Han G
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e491-e492. PubMed ID: 28502119
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
16. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
Vergou T; Moustou AE; Antoniou C
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
[No Abstract] [Full Text] [Related]
17. Different Responses to Ustekinumab of Two HLA-Cw6-positive Homozygous Twins with Psoriasis.
Burlando M; Cozzani E; Campisi C; Di Costanzo A; Parodi A
Acta Derm Venereol; 2016 Aug; 96(6):858-9. PubMed ID: 26714660
[No Abstract] [Full Text] [Related]
18. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
19. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
[TBL] [Abstract][Full Text] [Related]
20. Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.
Onderdijk AJ; Ijpma AS; Menting SP; Baerveldt EM; Prens EP
Br J Dermatol; 2015 Dec; 173(6):1536-9. PubMed ID: 26134667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
